Dataset Information

PEGylated AdipoRon Analogs Improve Glucose Homeostasis and Lipid Metabolism in Mice under Insulinopenic and High Fat Diet Conditions

ABSTRACT: Since the first report of AdipoRon as an orally active adiponectin receptor (AdipoR1/2) agonist, several studies have investigated its protective, metabolic and anti-cancer effects in the liver, kidney, heart, central nervous system and ovaries. Despite that, the effects of AdipoRon on pancreatic -cell function are yet to be addressed. Furthermore, the various AdipoRon actions reported to date have only been assessed at a rather high oral dosage without attempts to enhance its affinity and/or bioavailability. To examine how structural modifications can affect AdipoRon-induced multifaceted actions, we describe a series of AdipoRon analogs that contain amphiphilic ethylene glycol chains. Among these, we propose AdipoRonPEG5 as a more potent derivative of AdipoRon in exerting pleiotropic actions in mice under insulinopenic and high fat diet (HFD) conditions. While both AdipoRon and AdipoRonPEG5 substantially attenuate palmitate-induced lipotoxicity in INS-1 cells in a dose-dependent manner, only AdipoRonPEG5 treatment is accompanied by a marked expression of genes involved in maintaining the functional state of β-cells along with a significant reduction in ceramides. Similarly, AdipoRonPEG5 can induce a substantial reduction of pancreatic, hepatic and serum ceramide species, with a concomitant increase in the corresponding sphingoid bases, and improves insulin sensitivity of mice under HFD feeding conditions. Furthermore, hyperglycemia in STZ-induced insulinopenic adiponectin null mice is also attenuated upon AdipoRonPEG5 treatment. Our results suggest that AdipoRonPEG5 is more effective in reducing lipotoxicity in the pancreas and liver of HFD-fed mice than AdipoRon at 5 mg/Kg dosage and is consistent with adiponectin cytoprotective effect of β-cells. Additionally, these results indicate that the beneficial effects AdipoRonPEG5 can be partially attributed to improved pharmacokinetics compared to AdipoRon, thus providing the opportunity for further derivatization to achieve improved affinity and tissue-specific targeting.

ORGANISM(S): Mus musculus

PROVIDER: GSE155410 | GEO | 2021/03/15

REPOSITORIES: GEO

ACCESS DATA

Shared Molecules

Only show the datasets with similarity scores above: 0.5

Threshold

0.5

Similar Datasets

Project description:Abstract Background In obesity, adipose tissue undergoes a remodeling process characterized by increased adipocyte size (hypertrophia) and number (hyperplasia). The individual ability to tip the balance toward the hyperplastic growth, with recruitment of new fat cells through adipogenesis, seems to be critical for a healthy adipose tissue expansion, as opposed to the development of inflammation and detrimental metabolic consequences. However, the molecular mechanisms underlying this fine-tuned regulation are far from being understood. Methods We analyzed by mass spectrometry-based proteomics visceral white adipose tissue (vWAT) samples collected from C57BL6 mice fed with a HFD for 8 weeks. A subset of these mice, called low responders (LowR HFD), showed a low susceptibility to the onset of adipose tissue inflammation, as opposed to their HFD counterpart. We identified the discriminants between LowR HFD and HFD vWAT samples and explored their function in Adipose Derived human Mesenchymal Stem Cells (AD-hMSCs) differentiated to adipocytes. Results We quantified 6051 proteins. Among the candidates that most differentiate LowR HFD from HFD vWAT, we found proteins involved in adipocyte function, including adiponectin and hormone sensitive lipase, suggesting that adipocyte differentiation is enhanced in LowR HFD, as compared to HFD. The chromatin modifier SET and MYND Domain Containing 3 (SMYD3), whose function in adipose tissue was totally unknown, was another top-scored hit. SMYD3 expression was significantly higher in LowR HFD vWAT, as confirmed by western blot analysis. In vitro, we found that SMYD3 mRNA and protein levels decrease rapidly along the differentiation process of AD-hMSCs. Moreover, SMYD3 knock-down at the beginning of adipocyte differentiation resulted in reduced cell proliferation and, at longer term, reduced lipid accumulation in adipocytes. Conclusions Our study describes for the first time the role of SMYD3 as a regulator of adipocyte proliferation during the early steps of adipogenesis.